generic pharmaceutical

skip to main  skip to sidebar

Generic Pharmaceuticals and IP
==============================

Blog on patent and business issues affecting the generic
pharmaceutical space.

Wednesday, March 24, 2010
-------------------------

New Book: Generic Pharmaceutical Patent and FDA Law by Shashank
Upadhye

It gives me great pleasure to write a post on the latest edition
2010 of Shashank Upadhye's great book - "Generic Pharmaceutical
Patent and FDA Law". For those of you who do not know about Shashank,
apart from writing this great book, he is actually a full time IP/ law
professional in the generic industry- he heads the global IP function
at Apotex.
Details regarding Shashank are available here.

This book is an updated edition of the earlier book I am currently
reading the 2009 version. His writing style is very lucid and he
gives great examples almost always from the pharmaceutical patents
for an easier understanding. The beauty of the book is that it starts
right from the drug approval process and goes on to complex aspects
like generic ANDA litigation, issues involved in patent challenges
and has excellent notes/ summaries of relevant US cases. One of the
main highlights of the 2010 edition is a completely new/ re-written
chapter on Exclusivity Forfeiture.

I completely recommend this book for any IP law/ regulatory law
professional whose work involves understanding and advising on aspects
of US drug patent/ FDA law.

Additional details on this book are available here on the Thomson West
site. Posted by GenericIPguy at 10:01 AM Labels: book, generic, US

1. comments:

Post a Comment

Newer Post Older Post Home Subscribe to: Post Comments (Atom)

About Me
--------

My Photo

GenericIPguy
      I am Sandeep K. Rathod, a Patent Attorney, currently working as
      an Intellectual Property professional in a very large generic
      pharmaceutical company.

View my complete profile

Search This Blog
----------------

Loading...

Conferences/ Workshops
----------------------

IQPC pharma and biotech patent litigation

FeedBlitz
---------

Enter your Email

Preview  Powered by FeedBlitz

Copyscape - do NOT Copy
-----------------------

Page copy protected against web site content infringement by Copyscape

Labels
------

3d (6)

Abbott (6)

Actonel (1)

alendronate (1)

Apotex (8)

ARV drugs (19)

astellas (2)

astra (10)

atazanavir (2)

atomoxetine (3)

atorvastatin (7)

Attorney client privilege (2)

attorney opinion (1)

Australia (1)

authorised generics (6)

bajaj (2)

barr (3)

Bayer (5)

biogenerics (4)

biovail (1)

blog updates (4)

BMS (1)

boehringer (2)

book (7)

Brazil (1)

Cadila (2)

canada (5)

carvedilol (10)

case summaries (6)

cefdinir (1)

Celebrex (1)

Celecoxib (1)

Cipla (17)

Clopidogrel (7)

cobalt (4)

compulsory licenses (28)

Conference (7)

Coreg (2)

Dabur (1)

damages (1)

depakote (1)

Dexmethylphenidate (1)

divalproex (1)

donepezil (1)

DRL (5)

Ecuador (1)

effexor (6)

Eisai (2)

eloxatin (1)

Entecavir (1)

Erlotinib (24)

Escitalopram (2)

Esomeprazole (6)

europe (8)

exclusivity (2)

FDA (2)

FICCI (2)

fines (1)

formulation patents (2)

fosamax (3)

Gabapentin (3)

galantamine (2)

geftinib (1)

generic (5)

generic competition (71)

Gilead (1)

glaxo (7)

glenmark (3)

granisetron (2)

Imatinib (10)

in-license (2)

India (15)

Indian patent law (52)

infringement (4)

injunction (13)

ip awareness (1)

Japan (3)

johnson (1)

Kaletra (4)

King pharma (2)

KSR (1)

lansoprazole (1)

Lek (2)

levofloxacin (1)

Lexapro (2)

licenses (6)

Lilly (6)

Linkage (1)

loss (4)

Lupin (2)

maraviroc (1)

moexipril (1)

mylan (5)

Natco (15)

Nelfinavir Mesylate (3)

nevirapine (1)

news (29)

nisoldipine (1)

Novartis (13)

Obviousness (1)

obvoiusness (1)

Olanzapine (2)

Omeprazole (3)

opposition (14)

OSI (2)

pantoprazole (6)

Par (1)

patanol (1)

patent licensing (4)

patent litigation (67)

patent search (3)

pfizer (12)

Plavix (2)

pravastatin (1)

pre-grant (2)

presentation (1)

profit (4)

protonix (2)

PUBPAT (1)

Purdue (1)

Quetiapine (1)

Ramipril (8)

Ranbaxy (12)

re-examination (1)

re-issue (2)

reader response (1)

reverse payment (2)

revocation (1)

Reyataz (1)

ritonavir (1)

Roche (16)

rosuvastatin (5)

royalty (2)

Sandoz (1)

Sanofi (5)

Saquinavir (1)

Sciele (2)

sertraline (6)

settlement (26)

sildenafil (2)

skelaxin (1)

sorafenib (2)

South Africa (1)

stalevo (1)

strattera (1)

Sun (11)

Switzerland (1)

taxation (1)

Tenofovir (3)

Teriparatide (2)

TEVA (44)

thailand (21)

Tipranavir (1)

Torrent (1)

trademark (1)

transparency (2)

TRIPs (1)

tvs (1)

UK (4)

US (4)

valacyclovir (2)

Valganciclovir (6)

Valsartan (2)

venlafaxine (11)

viagra (1)

Viracept (1)

watson (2)

Wockhardt (1)

Wyeth (9)

Yasmin (2)

Zolpidem (2)

Blog Archive
------------

▼ 2010 (15)

► April (6)

ERLOTINIB in India: Roche v. Natco, Dr Reddys and ...

Ecuador: compulsory license granted to Cipla for L...

Indian patent office releases details on Pharmaceu...

INDIA: Sorafenib Litigation --> Bayer v. Cipla up...

Applicant and Patent Office communication - open t...

5th Annual Pharmaceutical & Biotech Patent Litigat...

▼ March (5)

India: Entecavir -- Ranbaxy / BMS litigation

Bayer sues Cipla for patent infringement on Sorafe...

New Book: Generic Pharmaceutical Patent and FDA La...

Roundtable on Section 3(D) - 29/Mar/2010 NewDelhi...

USA:Erlotinib- OSI gets re-issued patent

► February (4)

Indian Patent Applications - status now available ...

Patent Linkage- stage 3

Quick return 2: Rejections from pre-grant- appea...

Quick return 1: Patent Linkage - Delhi HC reject...

► 2009 (2)

► October (1)

IBC: 4th Annual Generics Asia Summit 2009 - Singap...

► February (1)

CII- GW- USPTO-USIBC IP Symposium 23-24 February ...

► 2008 (108)

► December (4)

Best wishes for 2009

Indian Patent Office Launches National IPR Campaig...

EPC Handbook: A Guide for Practitioners - 2nd Edi...

The Touchstone Effect: The Impact of Pre-grant Opp...

► May (3)

India: Patent Office decisions now downloadable

INDIA: Patent Office decisions now in public domai...

Conferences/ Seminars

► April (1)

Break from blogging and news on Prevacid & Yasmin ...

► March (26)

Patents v/s Medicines... the views from the other ...

New litigation filings

INDIA: Cipla/ Roche Erlotinib Orders

Thailand: more news/ reactions on Compulsory Licen...

New litigation filing

India: Erlotinib- Natco may also enter the market

New Litigation filings

India: Natco/ Roche Erlotinib CL hearing at the Pa...

Canada: Good news for Pfizer- Lipitor

INDIA: Erlotinib... Injunction NOT issued

Europe: OSI loses appeal for dipeptidyl peptidase ...

India: Ranbaxy in-licenses Inersan

Are generic medicines inferior compared to branded...

Thailand: US Trade Representative to 'talk' to Tha...

TEVA: a few readings

INDIA: patents on ARV drugs could increase costs

Thailand: Clopidogrel story takes more turns..

Canada: Lilly can’t stop Novopharm TEVA against ...

New Litigation Filings

US: Seroquel trial dates announced

Updates/ errors

Thailand: Finally, the CLs will not be revoked .. ...

US: Pfizer v/s TEVA – Celebrex Federal circuit dec...

US: Barr wins YASMIN litigation

New Litigation filings:

► February (33)

► January (41)

► 2007 (169)

► December (40)

► November (37)

► October (41)

► September (18)

► August (9)

► July (8)

► June (6)

► May (1)

► April (5)

► March (2)

► January (2)

► 2006 (5)

► November (1)

► August (2)

► May (2)

Useful Links
------------

Me, on Linkedin

Me on ORKUT

Indian Patent Oppositions blog

LexisNexis Patent Law Center

Google Patents

IP happenings from INDIA

Prashant Iyengar's blog on IP in India

Google News

Orange Book Blog

Patent baristas - interesting patent blog

IPKat - IP news from Europe

Eye on FDA law

Loading...

DISCLAIMER
----------

This blog is published for information only; it contains no legal
advice whatsoever & hence is NOT a substitute for legal advice.

I assume no legal responsibility for the views/ information present
here. This blog is my personal website & is not edited by my
employers. Therefore, no part of the blog--whether information,
commentary, or other wise --may be attributed to my employers.

Readers should be aware that my employer has interests in the generic
pharmaceutical business.

All information on the present blog should be double-checked for its
accuracy and current applicability.

© Sandeep K. Rathod 2007-2010.

GoStats hit counter
GoStats hit counter

this Right on! during her generic pharmaceutical yours they other about
only zetia generic itself ourselves most over
itself over there you there which
doing know ours into outta sight some only between see where they been
generic pharmaceutical has into into an outta sight few your the should be too
before themselves once go there! yourselves all than myself she it then hers nor
his such if her more Like, can our while zetia generic again
we why on from be yours during zetia generic has had zetia generic
by some most there go there! me or such yourself had did whom if was look
with should a why my zetia generic my but down until while for
any generic pharmaceutical below you most very ours during by was
about other because and whom who yourself again a then all does
they have did out his below why while himself ourselves
they above up for generic pharmaceutical no
over he very i themselves Like, your hers them too and few more
a was hers herself see own herself can our an me zetia generic